Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants

References

• Bayer PharmaAGXarelto^® (rivaroxaban) Summary of Product Characteristics2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdfAccessed April 13, 2017
   Google Scholar
• Boehringer Ingelheim International GmbHPradaxa® (dabigatran etexilate) Summary of Product Characteristics2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdfAccessed April 13, 2017
   Google Scholar
• Bristol-Myers Squibb and PfizerEliquis® (apixaban) Summary of Product Characteristics2017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdfAccessed April 13, 2017
   Google Scholar
• Daiichi Sankyo Europe GmbHLixiana® (edoxaban) Summary of Product Characteristics2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdfAccessed April 13, 2017
   Google Scholar
• HeidbuchelHVerhammePAlingsMUpdated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillationEuropace2015171467150726324838
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med20093611139115119717844
   PubMed Web of Science ®Google Scholar
• GiuglianoRPRuffCTBraunwaldEEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med20133692093210424251359
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med201136598199221870978
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPBraunwaldEComparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsLancet201438395596224315724
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med201136588389121830957
   PubMed Web of Science ®Google Scholar
• HankeyGJStevensSRPicciniJPIntracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct Factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillationStroke2014451304131224743444
   PubMed Web of Science ®Google Scholar
• HartRGDienerHCYangSIntracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trialStroke2012431511151722492518
   PubMed Web of Science ®Google Scholar
• HylekEMHeldCAlexanderJHMajor bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomesJ Am Coll Cardiol2014632141214724657685
   PubMed Web of Science ®Google Scholar
• PicciniJPGargJPatelMRManagement of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trialEur Heart J2014351873188024658769
   PubMed Web of Science ®Google Scholar
• LippiGArdissinoDQuintavallaRCervellinGUrgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory testsJ Thromb Thrombolysis20143826927424811247
   PubMed Web of Science ®Google Scholar
• AgenoWGallusASWittkowskyACrowtherMHylekEMPalaretiGOral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest2012141e44Se88S22315269
   PubMed Web of Science ®Google Scholar
• DiasJDNoremKDoorneweerdDDThurerRLPopovskyMAOmertLAUse of thromboelastography (TEG) for detection of new oral anticoagulantsArch Pathol Lab Med201513966567325927150
   PubMed Web of Science ®Google Scholar
• ChojnowskiKGorskiTRobakMTrelinskiJEffects of rivaroxaban therapy on ROTEM coagulation parameters in patients with venous thromboembolismAdv Clin Exp Med201524995100026771971
   PubMedGoogle Scholar
• SamamaMMMartinoliJLLe FlemLAssessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitorThromb Haemost201010381582520135059
   PubMed Web of Science ®Google Scholar
• HillRAChungHGeorgeELongsonCStevensAPrasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention: NICE technology appraisal guidanceHeart2010961407140820801857
   PubMedGoogle Scholar
• DouxfilsJMullierFLoosenCChatelainCChatelainBDognéJMAssessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literatureThromb Res201213095696623006523
   PubMed Web of Science ®Google Scholar
• Lindhoff-LastEAnsellJSpiroTSamamaMMLaboratory testing of rivaroxaban in routine clinical practice: when, how, and which assaysAnn Med20134542342923746003
   PubMed Web of Science ®Google Scholar
• CasuttMKonradCSchuepferGEffect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEMAnaesthesist20126194895323053307
   PubMedGoogle Scholar
• EllerTBusseJDittrichMDabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function testsClin Chem Lab Med20145283584424406289
   PubMed Web of Science ®Google Scholar
• OswaldEVelik-SalchnerCInnerhoferPResults of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort studyBlood Coagul Fibrinolysis20152613614425396759
   PubMedGoogle Scholar
• MolenaarPJDinkelaarJLeyteAMeasuring rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generationClin Chem Lab Med2012501799180723089710
   PubMedGoogle Scholar
• GarciaDBarrettYCRamacciottiEWeitzJILaboratory assessment of the anticoagulant effects of the next generation of oral anticoagulantsJ Thromb Haemost201311224525223216682
   PubMed Web of Science ®Google Scholar
• SalmonsonTDogneJMJanssenHBurgosJGBlakePNon-vitamin-Koral anticoagulants and laboratory testing: now and in the futureEur Heart J Cardiovasc Pharmacother201731424728025213
   PubMed Web of Science ®Google Scholar
• DinkelaarJMolenaarPJNinivaggiMde LaatBBrinkmanHJLeyteAIn vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for RivaroxabanJ Thromb Haemost20131161111111823578206
   PubMed Web of Science ®Google Scholar
• RathbunSTafurAGrantREsmonNMauerKMarlarRAComparison of methods to determine rivaroxaban anti-Factor Xa activityThromb Res201513539439725476589
   PubMed Web of Science ®Google Scholar
• FavaloroEJLippiGLaboratory testing in the era of direct or nonvitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errorsSemin Thromb Hemost20154120822725703514
   PubMedGoogle Scholar
• HillarpAGustafssonKMFaxälvLEffects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assaysJ Thromb Haemost2014121545155324965851
   PubMed Web of Science ®Google Scholar
• TripodiAPadovanLTestaSHow the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform studyClin Chem Lab Med20155326527325153405
   PubMedGoogle Scholar
• DouxfilsJChatelainCChatelainBDognéJMMullierFImpact of apixaban on routine and specific coagulation assays: a practical laboratory guideThromb Haemost201311028329423765180
   PubMed Web of Science ®Google Scholar
• CukerAHusseinzadehHLaboratory measurement of the anticoagulant activity of edoxaban: a systematic reviewJ Thromb Thrombolysis20153928829425669624
   PubMed Web of Science ®Google Scholar
• DouxfilsJChatelainBChatelainCDognéJMMullierFEdoxaban: impact on routine and specific coagulation assays. A practical laboratory guideThromb Haemost201611536838126510969
   PubMed Web of Science ®Google Scholar
• IbaTEmmiMHikiMComparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effectInt J Hematol201610366567226984594
   PubMed Web of Science ®Google Scholar
• van RynJStangierJHaertterSDabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activityThromb Haemost20101031116112720352166
   PubMed Web of Science ®Google Scholar
• DouxfilsJMullierFRobertSChatelainCChatelainBDognéJMImpact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilateThromb Haemost201210798599722438031
   PubMed Web of Science ®Google Scholar
• HonickelMTreutlerSvan RynJTillmannSRossaintRGrottkeOReversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumabThromb Haemost201511372874025567155
   PubMed Web of Science ®Google Scholar
• SolbeckSOstrowskiSRStensballeJJohanssonPIThrombelastography detects dabigatran at therapeutic concentrations in vitro to the same extent as gold-standard testsInt J Cardiol2016208141826826624
   PubMed Web of Science ®Google Scholar
• MorishimaYKamisatoCLaboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assayAm J Clin Pathol201514324124725596250
   PubMed Web of Science ®Google Scholar
• BurnettAEMahanCEVazquezSROertelLBGarciaDAAnsellJGuidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatmentJ Thromb Thrombolysis20164120623226780747
   PubMed Web of Science ®Google Scholar
• HaasSBodeCNorrvingBTurpieAGGPractical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and riskVasc Health Risk Manag20141010111424648742
   PubMedGoogle Scholar
• ReillyPALehrTHaertterSThe effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)J Am Coll Cardiol20146332132824076487
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPBraunwaldEAssociation between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trialLancet20153852288229525769361
   PubMed Web of Science ®Google Scholar
• DouxfilsJChatelainBHjemdahlPDoes the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort studyThromb Res201513585286025743887
   PubMed Web of Science ®Google Scholar
• TsakirisDADirect oral anticoagulants – interference with laboratory tests and mechanism of actionSemin Hematol2014519810124861793
   PubMed Web of Science ®Google Scholar
• WeitzJIPollackCVJrPractical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulantsThromb Haemost20151141113112626155974
   PubMed Web of Science ®Google Scholar
• LevyJHAgenoWChanNCWhen and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTHJ Thromb Haemost20161462362726911798
   PubMed Web of Science ®Google Scholar
• PollackCVJrReillyPAEikelboomJIdarucizumab for dabigatran reversalN Engl J Med201537351152026095746
   PubMed Web of Science ®Google Scholar
• GhadimiKDombrowskiKELevyJHWelsbyIJAndexanet alfa for the reversal of Factor Xa inhibitor related anticoagulationExpert Rev Hematol2016911512226686866
   PubMed Web of Science ®Google Scholar
• KearonCAklEAOrnelasJAntithrombotic therapy for VTE disease: CHEST guideline and expert panel reportChest201614931535226867832
   PubMed Web of Science ®Google Scholar
• PernodGAlbaladejoPGodierAManagement of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or Factor-Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013Arch Cardiovasc Dis201310638239323810130
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMRothAMueckWDose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjectsCurr Med Res Opin2008242757276518715524
   PubMed Web of Science ®Google Scholar
• LetertreLRGudmundsdottirBRFrancisCWA single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin and enoxaparin in plasmaJ Thromb Haemost2016141043105326924677
   PubMed Web of Science ®Google Scholar
• MueckWStampfussJKubitzaDBeckaMClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanClin Pharmacokinet20145311623999929
   PubMed Web of Science ®Google Scholar
• SongSKangDHalimABMillerRPopulation pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatmentJ Clin Pharmacol20145491091624706516
   PubMed Web of Science ®Google Scholar